FB-TW

Showing posts with label heart failure. Show all posts
Showing posts with label heart failure. Show all posts

Friday, June 7, 2013

Preventing Glucose-Induced Cardiovascular Damage - Michaels

Preventing Glucose-Induced Cardiovascular Damage

Conditions Associated With Elevated Blood Glucose and Advanced Glycation End Products
Elevated cholesterol and atherosclerosis49,50
Symptoms of carotid artery atherosclerosis (major risk for stroke)51
Risk of developing high risk cardiac rhythm disturbances following heart attack52
Cataracts of the eye35
Overall risk of developing cancer53
Risk of developing fatal cancer54
Increased prostate size in benign prostatic hyperplasia (BPH)55
Abnormal elevation in liver enzymes, markers of liver damage56
Incidence and severity of obstructive sleep apnea57
Blood vessels are lined by a thin layer of cells called the endothelium which constantly regulates blood pressure and flow. Damage to the endothelium, which occurs in response to elevated glucose levels, is an important first step in producing heart attacks, heart failure, and stroke.

Studies now show that benfotiamine can prevent endothelial dysfunction and substantially improve blood vessel and heart muscle function, even in the face of glucose-induced tissue damage.

The process of healthy endothelial cell replication is vital to maintaining healthy arteries. Excess levels of glucose can reduce endothelial cell replication. The addition of benfotiamine to endothelial cells grown in a high-glucose environment corrects the defective replication. Benfotiamine accomplishes this through normalization of advanced glycation end product production.

High glucose levels also trigger early death of endothelial cells through the process called apoptosis; benfotiamine supplementation reverses increased apoptosis in cultures of endothelial cells by several mechanisms.

The body produces toxic alcohol-like compounds called polyols during periods of high blood sugar. Polyols disrupt endothelial and cardiovascular cell function. Benfotiamine reduces production of polyols, accelerates the rate of glucose breakdown, and reduces free glucose levels within cells. All of these effects further contribute to protection of endothelial cell function.

After a heart attack, or as a result of persistently high blood pressure, heart muscle cells beat more weakly than they should, resulting in heart failure. High glucose levels and advanced glycation end products substantially contribute to this diminished heart muscle function. Studies show that benfotiamine abolishes many of the abnormalities in heart muscle cell contractility, which may "rescue" impaired heart muscle and improve its ability to pump blood effectively. Benfotiamine activates important cell survival signaling pathways in heart muscle cells failing under the effects of elevated glucose.

Preventing Glucose-Induced Cardiovascular Damage
Atherosclerosis
Not all advanced glycation end products (AGEs) are produced internally in the body. Consuming a meal rich in AGEs (such as one abundant in browned meats or caramelized sugars) can increase blood levels of AGEs and impair endothelial function. Supplementation with benfotiamine, 1,050 mg/day for 3 days, completely prevented the changes in endothelial function and blood flow produced by such a meal in a group of human subjects.

In addition to its effective control of AGE-related endothelial dysfunction, benfotiamine exerts powerful direct antioxidant effects. In rats with experimentally induced vascular endothelial dysfunction, benfotiamine reduced oxidative stress and enhanced favorable generation of nitric oxide, a compound that contributes to blood vessel relaxation.33,34 The result was an improvement in endothelial integrity and function.

All of these endothelium-protecting effects make benfotiamine an essential nutrient in your fight against the devastating effects of elevated blood glucose on your cardiovascular system.
=====================================================================
Read the complete article here.

Sunday, May 5, 2013

Fears of cancer link to statin - AB Rossebo,

Scientists raise fears of cancer link to statin used by thousands


 
This post includes a synopsis of a study published in the New England Journal of Medicine September 25, 2008; 359(13): 1343-56 and a recipe for roccoli, bacon and nut salad.

Study title and authors:

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
AB Rossebo, TR Pedersen, K Boman, P Brudi, JB Chambers, K Egstrup, E Gerdts, C Gohlke-Barwolf, I Holme, YA Kesaniemi, W Malbecq, CA Nienaber, S Ray, T Skjaerpe, K Wachtell, R Willenheimer, and SEAS Investigators Division of Cardiology, Aker University Hospital, Trondheimsveien 235, N-0514 Oslo, Norway.

This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/18765433

This trial observed the effects of the drug Inegy (a combination of simvastatin and ezetimibe).The trial was a randomizsd, double-blind trial involving 1,873 patients with mild-to-moderate, asymptomatic aortic stenosis (obstruction of blood flow across the aortic valve). The patients received either 40 mg of simvastatin plus 10 mg of ezetimibe or placebo daily and were followed for 52 months.

The study found:

(a) Those taking the simvastatin/ezetimibe combination had a 4% increased risk of death compared to those taking placebo.

(b) Those taking the simvastatin/ezetimibe combination had a 21% increased risk of death from heart failure compared to those taking placebo.

(c) Those taking the simvastatin/ezetimibe combination had a 67% increased risk of death from cancer compared to those taking placebo.

(d) Those taking the simvastatin/ezetimibe combination had a 195% increased risk of death from violence or accidents compared to those taking placebo.


Professor Heinz Drexel, of the University of Innsbruck in Austria and spokesman for the European Society of Cardiology, said: "I am not sure that the efficacy is proven and I am not sure that the safety is proven. I wouldn't take the drug myself".

In Britain, about 300,000 NHS prescriptions have been dispensed for Inegy in the last two years.
==================================================================
Read the complete article here.

Tuesday, March 12, 2013

Statins drugs cause heart disease.

New research shows that statins, drugs which lower cholesterol, cause heart disease.
 
New research shows that statins, drugs which lower cholesterol, cause heart disease. These drugs cause calcified plaques to form in coronary arteries in humans, thus causing or worsening heart disease.
A new study shows that the use of statins increases calcified plaque in coronary arteries. Coronary artery calcification (CAC) is a measure of coronary atherosclerosis, predicts coronary heart disease (CAD), and has been described as the strongest predictor of cardiac risk in patients with no symptoms. The study was led by Ryo Nakazato of the Cedars-Sinai Heart Institute and Department of Imaging, Cedars-Sinai Medical Center, Los Angeles and examined 6673 subjects with no known coronary heart disease. One group of 2413 was on statins and another group of 4260 wasn't on statins. Those who used statins had a higher prevalence of obstructive coronary artery disease and a higher number of coronary segments that had calcified plaques. The study was published in the journal Atherosclerosis.
Another recent study on diabetic subjects with advanced atherosclerosis also shows that frequent statin use causes accelerated coronary artery calcification. The study, published in the journal Diabetes Care,also shows that in those who weren’t initially using statins, the progression of coronary and abdominal artery calcification was significantly increased in those who used statins frequently.
Furthermore, another new study published in the Journal of the American College of Cardiology Foundation Cardiovascular Imaging also shows that CAC is associated with heart failure.
Thus statin drugs can cause coronary heart disease by increasing coronary artery calcification in healthy and diabetic subjects. Previous research has also shown that statins don’t reduce the risk of all-cause mortality. Because coronary artery calcification strongly predicts coronary heart disease, and statins increase artery calcification, their wide-spread use must be questioned.
If you use statins, discuss their use with your doctor, and preferably with a cardiologist.
CAC can be determined with electron beam computed tomography or multidetector computed tomography scan. Ask your cardiologist to undergo CAC scoring so you can evaluate the effects of the statins on your arteries and to make an educated decision if you should discontinue them or not.
Read more: http://digitaljournal.com/article/334943#ixzz2NHsPS6Y6

Thursday, March 7, 2013

Heart Failure Mortality Linked to Glucose Levels - Fiore

Heart Failure Mortality Linked to Glucose Levels

 
By Kristina Fiore, Staff Writer, MedPage Today
Published: January 17, 2013
Reviewed by F. Perry Wilson, MD, MSCE; Instructor of Medicine, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner
Serum glucose measured at the time of hospital admission predicted 30-day mortality in acute heart failure patients, researchers reported.
.
.
.

“Our results are consistent with basic and clinical science data linking an elevated blood glucose level with myocardial injury, impaired myocardial performance, arrhythmia, and risk of ventricular remodeling,” they wrote.

Elevated glucose has also been associated with worse outcomes for patients with stroke and other critical illnesses, the researchers said, but its short-term prognostic impact in acute heart failure isn’t known.

Mebazaa and colleagues analyzed data from a multi-national cohort of 6,212 acute heart failure patients who had a mean age of 72, and 41% of whom had a previous diagnosis of diabetes.

The mean blood glucose concentration on arrival at the hospital was 7.5 mmol/L (135 mg/dL), and after 30 days, 10% of the patients had died.

Mebazaa and colleagues found that patients who died had a significantly higher median blood glucose concentration at admission compared with survivors ...

The risk between blood sugar levels and 30-day mortality was consistent across all subgroups of patients, the researchers reported,
.
.
.

They also emphasized that the relationship between blood sugar and death was seen in patients both with and without a previous diagnosis of diabetes.

In sensitivity analyses, adjusting for factors such as left ventricular ejection fraction (LVEF) and plasma natriuretic peptides, as well as excluding patients from the largest cohort, didn’t significantly alter any of the findings.
.
.
.
The researchers said it was not clear whether elevated blood sugar in acute heart failure is “a marker for risk or a mediator of adverse outcomes” — but since serum glucose is “widely measured, easily interpreted, and inexpensive to measure,” using it in risk assessment is “worthy of consideration.”
The study was limited by a lack of data on glycated hemoglobin (HbA1c) at admission and by the absence of serial measurements of glucose during the hospital stay.

Further work is needed to better understand the pathophysiology and complete trajectory of hyperglycemia in acute heart failure, they concluded.
==============================================================
Read the complete article here.

Download Complimentary Source PDF



Friday, January 4, 2013

Could statins be adding to the epidemic of heart failure? - Briffa

Could statins be adding to the epidemic of ‘heart failure’?

Statins are drugs that reduce cholesterol by inhibiting an enzyme in the liver known as ‘HMG-CoA reductase’ which ‘drives’ cholesterol production (most of the cholesterol in the bloodstream is made in the liver and does not come directly from the diet). But HMG-CoA reductase also facilitates the production of a substance known as ‘coenzyme Q10’ which itself participates in the production of what is known as ‘adenosine triphosphate’ (ATP) – the most basic unit of energy ‘fuel’ in the body. The major biochemical process which involves CoQ10 that drives ATP and energy production in the body is known as ‘oxidative phosphorylation’.

Now that we have the potted biochemistry lesson over, we can see that statins have the potential, by lowering CoQ10 levels, to put a break on oxidative phosphorylation and ATP production in the muscles. The end result may be fatigue? Muscle pain is another potential consequence.

In a study published this week in the Journal of the American College of Cardiology (JACC), Danish researchers measured CoQ10 levels in individuals taking simvastatin (a commonly-prescribed statin), and compared them with those not taking statins [1]. The levels in those taking the statin were significantly lower.

Now, studies such as this one are what is termed ‘epidemiological’ in nature, which means it looks at associations between things, but cannot prove that one thing is causing another. However, of relevance here is other evidence which finds that giving statins to people does indeed have the capacity to lower levels of CoQ10 in the body [2].

What was also interesting about the JACC study is that it found that those treated with statins had lower levels of oxidative phosphorylation than those not taking them. They also had reduced ‘insulin sensitivity’. This is relevant for a number of reasons, including the fact that insulin facilitates the uptake of nutrients such as glucose into the cells. Lowered insulin sensitivity can therefore ‘starve’ the cells of essential nutrients. Reduced insulin sensitivity is also the underlying fault in type 2 diabetes. It is perhaps worth bearing in mind that statin use has been proven to increase the risk of type 2 diabetes.

Another thing worth bearing in mind here, I think, is the fact that the heart is a muscle, and depleting it of CoQ10 may be hazardous for cardiac health. Specifically, it may weaken the heart and lead to what is known as ‘heart failure’ (also known as ‘congestive cardiac failure’). I think the ‘benefits’ of statins are vastly overstated, generally speaking. However, if someone is to take statins, I think it’s a reasonable safeguard to take CoQ10 on a daily basis. 100 mg a day is a decent dose, I think, though higher doses are likely to better when symptoms of statin toxicity are present.

In researching this article, I came across an interesting review of the evidence for statin-inducted CoQ10 depletion in both humans and animals [3]. Here’s what the authors of this review have to say in their concluding remarks:
Statin-induced CoQ10 deficiency is completely preventable with supplemental CoQ10 with no adverse impact on the cholesterol lowering or anti-inflammatory properties of the statin drugs. We are currently in the midst of a congestive heart failure epidemic in the United States, the cause or causes of which are unclear. As physicians, it is our duty to be absolutely certain that we are not inadvertently doing harm to our patients by creating a wide-spread deficiency of a nutrient critically important for normal heart function.
References:
1. Larsen S, et al. Simvastatin Effects on Skeletal Muscle – Relation to Decreased Mitochondrial Function and Glucose Intolerance. J Am Coll Cardiol. 2013;61(1):44-53
2. Passi S, et al. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors 2003;18(1-4):113-24.
3. Langsjoen PH, et al. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors 2003;18(1-4):101-11.
=========================================================================================================
Read the complete article here.

Wednesday, January 2, 2013

Dangers of Statin Drugs - Seneff

Drug Side Effect Discovery from Online Patient-Submitted Reviews: Dangers of Statin Drugs



by Jingjing Liu, Alice Li and Stephanie Seneff MIT Computer Science & Artificial Intelligence Laboratory

Abstract—In recent years, consumers have become empowered to share personal experiences regarding prescription drugs via Web page discussion groups. This paper describes our recent research involving automatically identifying adverse reactions from patient-provided drug reviews on health-related web sites. We focus on the statin class of cholesterol-lowering drugs. We extract a complete set of side effect expressions from patient-submitted drug reviews, and construct a hierarchical ontology of side effects. We use log-likely ratio estimation to detect biases in word distributions when comparing reviews of statin drugs with age-matched reviews of a broad spectrum of other drugs. We find a highly significant correlation between statins and a wide range of disorders and conditions, including diabetes, amyotrophic lateral sclerosis (ALS), rhabdomyolysis, neuropathy, Parkinson’s disease, arthritis, memory loss, and heart failure. A review of the research literature on statin side effects corroborates many of our findings.

I. INTRODUCTION

The last few decades have witnessed a steady increase in drug prescriptions for the treatment of biometric markers rather than overt physiological symptoms. Today, people regularly take multiple drugs in order to normalize serum levels of biomarkers such as cholesterol or glucose, or to reduce blood pressure. All drugs have side effects, which are sometimes debilitating or even life-threatening. When a person taking multiple drugs experiences a new symptom, it is not always clear which, if any, of the drugs or drug combinations are responsible.
 
Increasingly, consumers are turning to the Web to seek information, and, increasingly, this information comes in the form of consumer-provided comments in discussion groups or chat rooms. User reviews of products and services have empowered consumers to obtain valuable data to guide their decision process. Recently, statistical and linguistic methods have been applied to large datasets of reviews to extract summary and/or rating information in various domains ([9] [22]).
 
Health care and prescription drugs are a growing topic of discussion online, not surprising given that almost half of all Americans take prescription drugs each month, costing over $200 billion in 2008 alone ([5]). Though drugs are subject to clinical trials before reaching market, these trials are often too short, and may involve too few people to give conclusive results. A large study recently conducted on the heart failure drug, nesiritude, invalidated the findings of the smaller study that had led to the drug’s approval [11]. While regulatory agencies do attempt to monitor the safety of approved medical treatments, surveillance programs such as the U.S. Food and Drug Administration’s (FDA’s) and Adverse Event Reporting System (AERS) are often difficult for patients to use.
 
In addition, the large language gap between medical documents and patient vocabulary can cause confusion and misunderstanding ([23]). We hope to take advantage of the vast amount of information available in patient anecdotes posted online to address the dual problems of insufficient clinical studies and mismatched terminology.
 
We envision a system that increases patient awareness of drug-related side effects by enabling consumers of prescription drugs to easily browse a large consolidated database of posts from health-related web sites. Beyond aggregating data from drug review and health discussion sites, we plan to support spoken queries, which would be answered via a set of succinctly summarized hits that best match the query, based on sophisticated statistical and linguistic techniques. The user could then click on any one of these displayed summaries to read the associated post.
 
This paper describes our preliminary efforts to detect associations between a drug class and its side effects. We use statistics and heuristic methods to build up a hierarchical ontology of side effects by aggregating patient-submitted drug reviews. We use log-likelihood ratios to extract summary information derived from biases in word and phrase distributions, and to quantify associations between drugs and symptoms. For the scope of this paper, we focus on statin drugs, which are among the most costly and commonly prescribed drugs in the United States. The methods described are applicable to all drug classes.
 
In the remainder of this paper, we will first review the research literature reflecting known or suspected side effects associated with statin drugs. After explaining our data collection and side-effect ontology construction, we describe our methodology and verify that many of our extracted associations align with observations from the literature.

II. BRIEF LITERATURE REVIEW

A. Side Effects of Statin drugs

Statins (Hydroxy methyl glutaryl coenzyme A reductase inhibitors) have become increasingly popular as very effective agents to normalize serum cholesterol levels. The most popular of these, atorvastatin, marketed under the trade name, Lipitor, has been the highest revenue branded pharmaceutical for the past 6 years. The official Lipitor web site lists as potential side effects mainly muscle pain and weakness and digestive problems. However, several practitioners and researchers have identified suspected side effects in other more alarming areas, such as heart failure, cognition and memory problems, and even severe

neurological diseases such as Parkinson’s disease and ALS (Lou Gehrig’s disease). [21] provides compelling arguments for the diverse side effects of statins, attributing them mainly to cholesterol depletion in cell membranes.
 
It is widely acknowledged that statin drugs cause muscle pain, weakness and damage ([7] [12]), likely due in part to their interference with the synthesis of the potent antioxidant Coenzyme Q10 (CoQ10) ([10]). CoQ10 plays an essential role in mitochondrial function to produce energy. Congestive heart failure is a condition in which the heart can no longer pump enough blood to the rest of the body, essentially because it is too weak. Because the heart is a muscle, it is
plausible that heart muscle weakness could arise from longterm statin usage. Indeed, atorvastatin has been shown to impair ventricular diastolic heart performance ([14]). Furthermore, CoQ10 supplementation has been shown to improve cardiac function ([13] [20]).
 
The research literature provides plausible biological explanations for a possible association between statin drugs and neuropathy ([15] [24]). A recent evidence-based article ([1]) found that statin drug users had a high incidence of neurological disorders, especially neuropathy, parasthesia and neuralgia, and appeared to be at higher risk to the debilitating neurological diseases, ALS and Parkinson’s disease. The evidence was based on careful manual labeling of a set of self-reported accounts from 351 patients. A mechanism for such damage could involve interference with the ability of oligodendrocytes, specialized glial cells in the nervous system, to supply sufficient cholesterol to the myelin sheath surrounding nerve axons. Genetically-engineered mice with defective oligodendrocytes exhibit visible pathologies in the myelin sheath which manifest as muscle twitches and tremors ([16]).
 
Cholesterol depletion in the brain would be expected to lead to pathologies in neuron signal transport, due not only to defective myelin sheath but also to interference with signal transport across synapses ([17]). Cognitive impairment, memory loss, mental confusion, and depression were significantly present in Cable’s patient population ([1]). Wagstaff et al. ([19]) conducted a survey of cognitive dysfunction from AERS data, and found evidence of both short-term memory loss and amnesia associated with statin usage. Golomb et al. ([6]) conducted a study to evaluate evidence of statin-induced cognitive, mood or behavioral

changes in patients. She concluded with a plea for studies that “more clearly establish the impact of hydrophilic and lipophilic statins on cognition, aggression, and serotonin.”

B. Relationship between Cholesterol and Health

ALS and heart failure are both conditions for which published literature suggests an increased risk associated with statin therapy ([1] [10]). Indeed, for both of these conditions, a survival benefit is associated with elevated cholesterol levels. A statistically significant inverse correlation was found in a study on mortality in heart failure. For 181 patients with heart disease and heart failure, half of those whose serum cholesterol was below 200 mg/dl were dead three years after diagnosis, whereas only 28% of the patients whose serum cholesterol was above 200 mg/dl had died. In another study on a group of 488 patients diagnosed with ALS, serum levels of triglycerides and fasting cholesterol were measured at the time of diagnosis ([2]). High values for both lipids were associated with improved survival, with a p-value <0 .05.=".05." p="p">
 
A very recent study on the relationship between various measures of cholesterol status and health in the elderly came up with some surprising results, strongly suggesting that elevated cholesterol is beneficial for this segment of the population [18]. A study population initially over 75 years old was followed over a 17 year period beginning in 1990. In addition to serum cholesterol, a biometric associated with the ability to synthesize cholesterol (lathosterol) and a biometric associated with the ability to absorb cholesterol through the gut (sitosterol) were measured. For all three measures of cholesterol, low values were associated with a poorer prognosis for frailty, mental decline and early death. A reduced ability to synthesize cholesterol showed the strongest correlation with poor outcome. Individuals with high measures of all three biometrics enjoyed a 4.3 year extension in life span, compared to those for whom all measures were low.

III. SIDE-EFFECT DISCOVERY

A. Data Collection

To learn the underlying associations between side effects and drug usage from patient-provided reviews, we collected drug reviews from three drug discussion forums (“AskPatient.com,” “Medications.com” and “WebDB.com”) which allow users to post reviews on specific drugs and share their experiences. Table 1 gives the statistics on the review data collection. A total of 8,515 statin reviews were collected from the three data sources. We also collected 105K drug reviews from the AskPatient.com, on drugs to treat a broad range of problems such as depression, acid reflux disease, high blood pressure, diabetes, etc. This set includes reviews for non-statin cholesterol lowering drugs.
 
Continue Reading the Research Study Here: http://people.csail.mit.edu/seneff/IMMM.pdf


Wednesday, April 18, 2012

Heart failure and vitamin D. But what about sunlight?


Heart failure and vitamin D. But what about sunlight?

18 April 2012 Barry Groves

 
Supports Chapter Eleven: Our irrational fear of sunlight
Vitamin D, just like all other vitamins, is essential not just to our health, but to life itself. Vitamin D is actually not really a vitamin, because our bodies can synthsize it from cholesterol in our skin with the action of the ultra-violet end of the spectrum of sunlight. But as the specific wavelength - UVB - is attenuated by the atmosphere, there is no point in sunbathing when the sun is low in the sky. We have to be in the sun, with as little clothing on as possible, and no sunscreen, when the sun is so high in the sky that our shadow is no longer than we are. In other words, in the middle of the day. But that is exactly what we are told by the 'experts' not to do!

There is very little food which contains vitamin D.
And vitamin D is one of the four fat-soluble vitamins (the others are A, E, and K). But fat is 'bad for us', isn't it! So the incompetent 'experts' also advise us to shun the only foods which can help.

It should come as no surprise, therefore, that severe vitamin D deficiency is a widespread health problem throughout the industrialised world.

Now a study just published in the European Journal of Heart Failure points out a growing serious health issue caused by this misguided advice. The Abstract of that study is below:


Israel Gotsman, Ayelet Shauer, Donna R. Zwas, et al. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail (2012) 14 (4):357-366.doi: 10.1093/eurjhf/hfr175

Abstract

Aims Vitamin D deficiency is a highly prevalent, global phenomenon. The prevalence in heart failure (HF) patients and its effect on outcome are less clear. We evaluated vitamin D levels and vitamin D supplementation in patients with HF and its effect on mortality.

Methods and results 25-Hydroxyvitamin D [25(OH)D] levels were evaluated in HF patients from a health maintenance organization (HMO), and compared them with those of the rest of the members of the HMO. Patients with HF (n = 3009) had a lower median 25(OH)D level compared with the control group (n = 46 825): 36.9 nmol/L (interquartile range 23.2–55.9) vs. 40.7 nmol/L (26.7–56.9), respectively, P < 0.00001. The percentage of patients with vitamin D deficiency [25(OH)D <25 nmol/L] was higher in patients with HF compared with the control group (28% vs. 22%, P < 0.00001). Only 8.8% of the HF patients had optimal 25(OH)D levels (≥75 nmol/L). Median clinical follow-up was 518 days. Cox regression analysis demonstrated that vitamin D deficiency was an independent predictor of increased mortality in patients with HF [hazard ratio (HR) 1.52, 95% confidence interval (CI) 1.21–1.92, P < 0.001] and in the control group (HR 1.91, 95% CI 1.48–2.46, P < 0.00001). Vitamin D supplementation was independently associated with reduced mortality in HF patients (HR 0.68, 95% CI 0.54–0.85, P < 0.0001). Parameters associated with vitamin D deficiency in HF patients were decreased previous solar radiation exposure, body mass index, diabetes, female gender, pulse, and decreased calcium and haemoglobin levels.

Conclusions Vitamin D deficiency is highly prevalent in HF patients and is a significant predictor of reduced survival. Vitamin D supplementation was associated with improved outcome.

CommentNote the last sentence. "Vitamin D supplementation" improves survival. So they only consider treating the problem after it has been caused. What's wrong with advising people to get out in the sun more?

Incidentally, I do get out in the sun as much as possible. It doesn't need a lot: half an hour a day at midday is sufficient. I had my serum vitamin D checked a couple of weeks ago. It was 150.8nmol/L. And I aim to keep it that way.
=================================================================
Read the complete article here.
Barry's blog is here.

Tuesday, January 25, 2011

Cost of cardiovascular disease to triple by 2030

Exerpts of an article from Prevention's The Heart.org. I do not know too much about Prevention' position on heart disease relative to mine (which should be quite obvious if you have read much of what I post here on Credible Evidence), but I thought there was some interesting observations made by Michael O'Riordan.

Please avail yourself of the link to the full article and their site for further insite from their perspective.

=========================================================



Cost of cardiovascular disease to triple by 2030


January 25, 2011
Michael O'Riordan

Dallas, TX - In the next 20 years, more than 40% of the US population is expected to have some form of cardiovascular disease, and this will triple the total direct medical costs of caring for hypertension, coronary heart disease, heart failure, stroke, and other forms of cardiovascular disease from the current $273 billion to more than $800 billion, according to a new policy statement from the American Heart Association (AHA) [1].

In addition, the AHA estimates that the prevalence of cardiovascular disease will increase by approximately 10% over the next 20 years given no changes to prevention and treatment trends. If some risk factors, such as diabetes and obesity, continue to increase rapidly, cardiovascular disease prevalence and associated costs might increase even more, write Dr Paul Heidenreich (Veteran Affairs Palo Alto Health Care System, CA) and colleagues in the report, published online January 24, 2011 in Circulation.

At present, cardiovascular disease is the leading cause of death in the US and accounts for 17% of overall healthcare expenditures. In the past, the medical costs of cardiovascular disease increased at an average annual rate of 6%, and this growth in costs has been associated with an increase in life expectancy. That said, there are "many opportunities to further improve cardiovascular health while controlling costs," according to the AHA.

Cardiovascular disease is largely preventable (emphasis by Bill Davis)

The latest 2030 prevalence estimates for hypertension, coronary heart disease, heart failure, and stroke are derived from the 1999-2006 National Health and Nutrition Examination Survey (NHANES) and Census Bureau population estimates for the years 2010 to 2030. Projections of the medical costs associated with cardiovascular disease used the 2001-2005 Medical Expenditure Panel Survey (MEPS) and did not double count expenditures resulting from individuals with multiple conditions.

By 2030, the prevalence of cardiovascular disease is expected to increase 9.9%, with the prevalence of heart failure and stroke increasing approximately 25%. Total direct costs will increase to $818 billion by 2030, according to the AHA estimates, and the total indirect cost to the US in terms of lost productivity is close to $275 billion.
.
.
.
.
.
Offering up a glass-half-full take on the data, Heidenreich and colleagues write that it is "fortunate that cardiovascular disease is largely preventable,"(emphasis by Bill Davis) and the healthcare system needs to focus on prevention and early intervention.
.
.
.


Jan 25, 2011 15:30 EST Source

1.Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States. Circulation 2011; DOI:10.1161/CIR.0b013e31820a55f5. Available at: http://circ.ahajournals.org.